News

The 2023 Annual Report of the Anticancer Fund is summarizing a year of achievements and efforts to challenge the course of cancer. The theme ‘Care today, a cure for tomorrow’ reflects our focus on delivering tailored patient support and advancing research, for more and better treatments. 

Are you working on innovative solutions for pancreatic cancer? We want to turn promising research into clinical trials. Apply now, the application is straightforward.

This funding will help turning laboratory research into clinical trials that could lead to new treatments.

On June 25, 2024, Santiago de Compostela will host a gathering of experts aimed at enhancing treatment options for patients with pancreatic cancer.

Organised by the Anticancer Fund and Pancreatic Cancer Europe, and supported by the European Pancreatic Club, this Multistakeholder Meeting seeks to foster an inclusive dialogue among professionals.

A clinical trial investigated propranolol, commonly used for high blood pressure, as a potential treatment for angiosarcoma, a rare and aggressive cancer. Funded by the Anticancer Fund, the study explored whether propranolol could help control tumour growth before traditional treatments start, aiming to increase the chances of survival.

The Anticancer Fund champions drug repurposing for cancer at the #iDR24 conference, taking place on March 6 and 7, 2024 in Barcelona. Identifying new uses for existing medicines, represents a significative opportunity for cancer patients.

We present the initial findings of the French-Belgian Metro-PD1 study testing a treatment with nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumours. The study reveals new possible treatment avenues for paediatric solid tumours. The results were published in the European Journal of Cancer.